IPSC Century Therapeutics Inc.
Drug Pipeline
| Drug | Stage | Notes |
|---|---|---|
|
CNTY-101
B-cell lymphoma
|
Phase 1
Phase 1
|
Phase 1 trial to be initiated 2H 2022.
|
Latest News
-
View Full Article Hide Full Article
Collaboration enables Century to explore Outpace's protein solutions for cell therapy to enhance functionality of iPSC platform
Initial program to focus on hematological malignancies with option to expand to additional candidates
PHILADELPHIA, Oct. 07, 2021 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ:IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, and Outpace Bio, a cutting-edge biotechnology company building a platform to create next-generation smart cell therapies today announced a research collaboration in CAR engineering.
The collaboration will bring together Century's CAR and protein engineering expertise with Outpace's protein design and synthetic biology capabilities to enhance CAR functionality by combining Outpace's optimized CAR spacer technology with Century's VHH domain binders.
"As an emerging leader in iPSC-based cell therapy, investing in cutting edge cell engineering technologies is central to our approach to develop transformational next generation allogeneic cell therapies," said Lalo Flores, Chief Executive Officer, Century Therapeutics. "The collaboration with Outpace will further enhance our protein engineering capabilities and potentially accelerate development of our proprietary next generation CARs."
"We are excited to work together with Century to create highly optimized CARs for their exciting iPSC-based cell therapies," said Marc Lajoie, CEO, and co-founder of Outpace. "This collaboration provides an ideal opportunity to accelerate the impact of Outpace's spacer technology, which is part of our broader platform to enhance T cell therapies, and in turn Outpace's protein design capabilities offer improved functionality and optionality to Century's iPSC platform and product candidates."
Under the terms of the agreement, Outpace will bring forward its spacer library and generate an in vitro data package of binder-spacer combinations for Century approval and selection of a candidate. Century will assess functionality in indication-relevant tumor models in vitro and in vivo.
About Century Therapeutics
Century Therapeutics (NASDAQ:IPSC) is harnessing the power of adult stem cells to develop curative cell therapy products for cancer that we believe will allow us to overcome the limitations of first-generation cell therapies. Our genetically engineered, iPSC-derived iNK and iT cell product candidates are designed to specifically target hematologic and solid tumor cancers. We are leveraging our expertise in cellular reprogramming, genetic engineering, and manufacturing to develop therapies with the potential to overcome many of the challenges inherent to cell therapy and provide a significant advantage over existing cell therapy technologies. We believe our commitment to developing off-the-shelf cell therapies will expand patient access and provide an unparalleled opportunity to advance the course of cancer care. For more information on Century Therapeutics please visit www.centurytx.com.
About Outpace Bio
Outpace Bio is creating next generation smart cell therapies using groundbreaking protein design and synthetic biology to reprogram how cells function and make decisions. Outpace collaborates with industry leaders to dramatically improve the safety and efficacy of cell and gene therapies, combining Outpace's mechanism-driven solutions with partners' biological insights, development capabilities, and clinical expertise to accelerate the discovery of curative therapies. With roots from David Baker's Lab at the University of Washington and Lyell Immunopharma, Outpace's versatile platform combines the design of improved biological functions with powerful cellular control modalities, harnessing the full complexity of cellular biology to tackle incurable disease. For more information visit outpacebio.com and follow on Twitter and Instagram @OutpaceBio.
Century Therapeutics Forward-Looking Statement
This press release contains forward-looking statements within the meaning of, and made pursuant to the safe harbor provisions of, The Private Securities Litigation Reform Act of 1995. All statements contained in this press release, other than statements of historical facts or statements that relate to present facts or current conditions, including but not limited to, statements regarding our cash and financial resources, our clinical development plans, and the development of our U.S. manufacturing facility are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as "may," "might," "will," "should," "expect," "plan," "aim," "seek," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "forecast," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this presentation are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition, and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond our control, including, among others: our ability to successfully advance our current and future product candidates through development activities, preclinical studies, and clinical trials; our reliance on the maintenance of certain key collaborative relationships for the manufacturing and development of our product candidates; the timing, scope and likelihood of regulatory filings and approvals, including final regulatory approval of our product candidates; the impact of the COVID-19 pandemic on our business and operations; the performance of third parties in connection with the development of our product candidates, including third parties conducting our future clinical trials as well as third-party suppliers and manufacturers; our ability to successfully commercialize our product candidates and develop sales and marketing capabilities, if our product candidates are approved; and our ability to maintain and successfully enforce adequate intellectual property protection. These and other risks and uncertainties are described more fully in the "Risk Factors" section of our most recent filings with the Securities and Exchange Commission and available at www.sec.gov. You should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur, and actual results could differ materially from those projected in the forward-looking statements. Moreover, we operate in a dynamic industry and economy. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties that we may face. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
Century Therapeutics Investor Contact:
Elizabeth Krutoholow
investor.relations@centurytx.com
267.857.1080Century Therapeutics Media Contact:
media@centurytx.com Outspace Bio Media Contact:
Allison Braley, Playground Global for Outpace Bio
press@playground.global
-
View Full Article Hide Full Article
PHILADELPHIA, Sept. 17, 2021 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ:IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced that it will be added to the small-cap Russell 2000® Index as a part of the 3Q21 Russell Indexes IPO additions, effective at US market open on September 20, 2021, according to the preliminary list of IPO additions to the Russell indexes.
"Century's inclusion in the Russell 2000 Index is an important milestone that reflects our continued progress toward advancing our lead therapeutic program, CNTY-101, into the clinic and to patients in need," said Lalo Flores, Ph.D., Chief Executive Officer of Century Therapeutics. "We are pleased to join the Russell Index and look forward to sharing our potential future growth with a broader audience of investors."
The Russell 2000® Index measures the performance of the small-cap segment of the U.S. equity market. Membership in the Russell 2000® Index, which remains in place until the next reconstitution, is based on membership in the broad market Russell 3000® Index. Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Approximately $10.6 trillion in assets are benchmarked against Russell's US indexes. Russell indexes are part of FTSE Russell, a leading global index provider.
For more information on the Russell 2000® Index and the Russell indexes reconstitution, visit the FTSE Russell website.
About Century Therapeutics
Century Therapeutics is harnessing the power of adult stem cells to develop curative cell therapy products for cancer that we believe will allow us to overcome the limitations of first-generation cell therapies. Our genetically engineered, iPSC-derived iNK and iT cell products are designed to specifically target hematologic and solid tumor cancers. We are leveraging our expertise in cellular reprogramming, genetic engineering, and manufacturing to develop therapies with the potential to overcome many of the challenges inherent to cell therapy and provide a significant advantage over existing cell therapy technologies. We believe our commitment to developing off-the-shelf cell therapies will expand patient access and provides an unparalleled opportunity to advance the course of cancer care. For more information, please visit www.centurytx.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of, and made pursuant to the safe harbor provisions of, The Private Securities Litigation Reform Act of 1995. All statements contained in this press release, other than statements of historical facts or statements that relate to present facts or current conditions, including but not limited to, statements regarding our our clinical development plans are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as "may," "might," "will," "should," "expect," "plan," "aim," "seek," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "forecast," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this press release are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition, and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond our control, including, among others: our ability to successfully advance our current and future product candidates through development activities, preclinical studies, and clinical trials; our reliance on the maintenance of certain key collaborative relationships for the manufacturing and development of our product candidates; the timing, scope and likelihood of regulatory filings and approvals, including final regulatory approval of our product candidates; the impact of the COVID-19 pandemic on our business and operations; the performance of third parties in connection with the development of our product candidates, including third parties conducting our future clinical trials as well as third-party suppliers and manufacturers; our ability to successfully commercialize our product candidates and develop sales and marketing capabilities, if our product candidates are approved; and our ability to maintain and successfully enforce adequate intellectual property protection. These and other risks and uncertainties are described more fully in the "Risk Factors" section of our most recent filings with the Securities and Exchange Commission and available at www.sec.gov. You should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur, and actual results could differ materially from those projected in the forward-looking statements. Moreover, we operate in a dynamic industry and economy. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties that we may face. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
Investor Contact:
Elizabeth Krutoholow
investor.relations@centurytx.com
267.857.1080Media Contact:
-
View Full Article Hide Full Article
Continued Company investment across our iPSC platforms, programs, and manufacturing
Lead program, CNTY-101, remains on track for IND filing in mid-2022
Recent IPO with net proceeds of approximately $221M
June 30, 2021 cash, cash equivalents, and marketable securities of $440MPHILADELPHIA, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Century Therapeutics, (NASDAQ:IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today reported financial results and business highlights for the second quarter ended June 30, 2021.
"With the proceeds raised from our IPO in June, we are well positioned to advance our lead candidate CNTY-101 toward clinical development, targeting IND filing in mid-2022," said Lalo Flores, Chief Executive Officer, Century Therapeutics. "We continue our investment in our iPSC platforms and are pleased with the progress achieved in developing iPSC-derived cell product candidates for the treatment of cancers with high unmet clinical need. We look forward to providing scientific updates on our programs and platform in the second half of 2021."
Recent Highlights
- Raised $221 million in public offering of common stock: In June 2021, the company announced a public offering of 10,550,000 shares of its common stock at a price of $20 per share. The underwriters also exercised their option to purchase an additional 1,582,500 shares of common stock for total offering net proceeds of $221 million.
- Expanded our Board of Directors: The Company appointed pharmaceutical industry veterans Alessandro Riva, M.D. and Kimberly Blackwell, M.D., as new Independent Directors.
- Continued manufacturing and technical operations investment: Our US manufacturing facility is expected to be operational by end of 2021.
Second Quarter 2021 Financial Results
- Cash Position: Cash, cash equivalents and marketable securities were $440.0 million as of June 30, 2021, as compared to $246.1 million as of March 31, 2021. This includes $221.2 million in net proceeds from the company's public offering in June 2021.
- Research and Development (R&D) expenses: R&D expenses were $18.9 million for the three months ended June 30, 2021, compared to $8.5 million for the same period in 2020.
General and Administrative (G&A) expenses: G&A expenses were $4.1 million for the three months ended June 30, 2021, compared to $2.3 million for the same period in 2020.
- Net loss: Net loss was $23.3 million for the three months ended June 30, 2021, compared to $15.3 million for the same period in 2020.
About Century Therapeutics
Century Therapeutics (NASDAQ:IPSC) is harnessing the power of adult stem cells to develop curative cell therapy products for cancer that we believe will allow us to overcome the limitations of first-generation cell therapies. Our genetically engineered, iPSC-derived iNK and iT cell product candidates are designed to specifically target hematologic and solid tumor cancers. We are leveraging our expertise in cellular reprogramming, genetic engineering, and manufacturing to develop therapies with the potential to overcome many of the challenges inherent to cell therapy and provide a significant advantage over existing cell therapy technologies. We believe our commitment to developing off-the-shelf cell therapies will expand patient access and provide an unparalleled opportunity to advance the course of cancer care. For more information on Century Therapeutics please visit https://www.centurytx.com/.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of, and made pursuant to the safe harbor provisions of, The Private Securities Litigation Reform Act of 1995. All statements contained in this press release, other than statements of historical facts or statements that relate to present facts or current conditions, including but not limited to, statements regarding our cash and financial resources, our clinical development plans, and the development of our U.S. manufacturing facility are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as "may," "might," "will," "should," "expect," "plan," "aim," "seek," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "forecast," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this presentation are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition, and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond our control, including, among others: our ability to successfully advance our current and future product candidates through development activities, preclinical studies, and clinical trials; our reliance on the maintenance of certain key collaborative relationships for the manufacturing and development of our product candidates; the timing, scope and likelihood of regulatory filings and approvals, including final regulatory approval of our product candidates; the impact of the COVID-19 pandemic on our business and operations; the performance of third parties in connection with the development of our product candidates, including third parties conducting our future clinical trials as well as third-party suppliers and manufacturers; our ability to successfully commercialize our product candidates and develop sales and marketing capabilities, if our product candidates are approved; and our ability to maintain and successfully enforce adequate intellectual property protection. These and other risks and uncertainties are described more fully in the "Risk Factors" section of our most recent filings with the Securities and Exchange Commission and available at www.sec.gov. You should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur, and actual results could differ materially from those projected in the forward-looking statements. Moreover, we operate in a dynamic industry and economy. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties that we may face. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
Investor Contact:
Investor.relations@centurytx.com
267.857.1080Media Contact:
media@centurytx.comCENTURY THERAPEUTICS, INC. AND SUBSIDIARY
CONSOLIDATED BALANCE SHEETS
(In thousands, except share amounts)June 30, 2021 December 31, (unaudited) 2020 Assets Current assets Cash and cash equivalents $ 272,277 $ 27,211 Short-term investments 125,290 48,542 Escrow deposits, current 419 783 Prepaid expenses and other current assets 4,625 2,261 Total current assets 402,611 78,797 Property and equipment, net 34,462 15,385 Operating lease right-of-use assets 12,251 9,392 Restricted cash 2,235 517 Escrow deposits, non-current 555 723 Long-term investments 42,474 1,053 Security deposits 1,042 909 Total assets $ 495,630 $ 106,776 Liabilities, convertible preferred stock, and stockholders' equity (deficit) Current liabilities Accounts payable $ 13,427 $ 8,082 Accrued expenses and other liabilities 6,832 4,030 Deposit liability 966 — Total current liabilities 21,225 12,112 Operating lease liability, long term 14,752 11,679 Deposit liability, non-current 2,268 — Long-term debt, net 9,788 9,636 Total liabilities 48,033 33,427 Commitments and contingencies Non-cumulative convertible preferred stock, Series A, $ 0.0001 par value, 0 and 35,000,000 shares authorized, issued and outstanding at June 30, 2021 and December 31, 2020, respectively — 34,922 Non-cumulative convertible preferred stock, Series B, $ 0.0001 par value, 0 and 26,143,790 shares authorized, issued and outstanding at June 30, 2021 and December 31, 2020, respectively — 144,839 Stockholders' equity (deficit): Preferred stock, $ 0.0001 par value, 10,000,000 and 0 shares authorized at June 30, 2021 and December 31, 2020, respectively, and 0 shares issued and outstanding — — Common stock, $0.0001 par value, 300,000,000 and 125,236,190 shares authorized; 54,404,091 and 7,481,861 shares issued and outstanding at June 30, 2021 and December 31, 2020, respectively 5 1 Additional paid-in capital 781,558 217,832 Subscription receivable — (31,900 ) Accumulated deficit (333,963 ) (292,342 ) Accumulated other comprehensive loss (3 ) (3 ) Total stockholders' equity (deficit) 447,597 (106,412 ) Total liabilities and stockholders' equity (deficit) $ 495,630 $ 106,776 CENTURY THERAPEUTICS, INC.
STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(Unaudited)
(In thousands, except share and per share amounts)Three Months Ended Three Months Ended Six Months Ended Six Months Ended June 30, 2021 June 30, 2020 June 30, 2021 June 30, 2020 Operating expenses Research and development $ 18,933 $ 8,484 $ 34,307 $ 16,427 General and administrative 4,088 2,310 6,776 4,360 Write off of in-process research and development asset - 4,722 - 4,722 Total operating expenses 23,021 15,516 41,083 25,509 Loss from operations (23,021 ) (15,516 ) (41,083 ) (25,509 ) Interest expense (318 ) — (632 ) — Other income, net 66 215 94 535 Net loss $ (23,273 ) $ (15,301 ) $ (41,621 ) $ (24,974 ) Net loss per common share Basic and Diluted (1.93 ) (2.05 ) (4.26 ) (3.34 ) Weighted average common shares outstanding Basic and Diluted 12,044,610 7,481,861 9,775,840 7,481,861 Other comprehensive loss Net loss $ (23,273 ) $ (15,301 ) $ (41,621 ) $ (24,974 ) Unrealized gain on short-term investments 32 97 5 124 Foreign currency translation adjustment (9 ) — (5 ) — Comprehensive loss $ (23,250 ) $ (15,204 ) $ (41,621 ) $ (24,850 ) 
-
View Full Article Hide Full Article
Record Year-to-Date Total Debt and Equity Commitments of $971.7 Million
Record Year-to-Date Total Fundings of $634.0 Million
Surpassed $12.0 Billion in Cumulative Total Debt Commitments since Inception
Q2 2021 Net Asset Value per Share Increased 3.1% to $11.71 from Q1 2021
Record Undistributed Earnings Spillover of $160.2 Million, or $1.38(1) per Ending Shares Outstanding
Q2 2021 Financial Achievements and Highlights
- Net Investment Income "NII" of $37.0 million, or $0.32 per share, an increase of 3.6% year-over-year
- Total Investment Income of $69.6 million, an increase of 2.3% year-over-year
-
Total gross new debt and equity commitments of $440.8 million
- Net Hercules' debt and equity commitments of $399.7 million(2)
-
Total gross fundings of $278.7 million
- Net Hercules' fundings of $246.9 million(2)
- Unscheduled early principal repayments or "early loan repayments" of $167.9 million
- $610.0 million of available liquidity, subject to existing terms and covenants
- 11.8% Return on Average Equity "ROAE" (NII/Average Equity)
- 5.9% Return on Average Assets "ROAA" (NII/Average Assets)
- GAAP leverage of 87.7% and regulatory leverage of 83.8%(3)
- Net Asset Value "NAV" increased to $11.71 from $11.36, an increase of 3.1% from Q1 2021
- 12.7% GAAP Effective Yield and 11.5% Core Yield(4), a non-GAAP measure
Year-to-date ending June 30, 2021 Financial Highlights
-
NII of $71.5 million, or $0.62 per share
- Total investment income of $138.3 million
-
Record new equity and debt commitments of $971.7 million, an increase of 85.8% year-over-year
- Record total fundings of $634.0 million, an increase of 73.3% year-over-year
- Net debt investment portfolio growth of $139.3 million
- Unscheduled early loan repayments of $359.4 million
Footnotes:
- $1.40 per Weighted Average Shares Outstanding
- Net Hercules' commitments and fundings are net of what was assigned to the private funds during the quarter
- Regulatory leverage represents debt-to-equity ratio, excluding the Company's Small Business Administration "SBA" debentures
- Core Yield excludes early loan repayments and one-time fees, and includes income and fees from expired commitments
Hercules Capital, Inc. (NYSE:HTGC) ("Hercules" or the "Company"), the largest and leading specialty financing provider to innovative venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, today announced its financial results for the second quarter ended June 30, 2021.
"During Q2 2021, Hercules generated 100% coverage of our base dividend distribution with NII, delivered solid NAV accretion and maintained our strong liquidity position to fund our disciplined and controlled growth strategy," stated Scott Bluestein, chief executive officer and chief investment officer of Hercules. "As a result, the Company was able to offset elevated repayment activities, deliver net debt portfolio growth of nearly $57 million and achieve the highest internal credit rating in our history. This strong operating performance extended the momentum from Q1, which led to record levels of new debt and equity commitments and total fundings of nearly $972 million and $634 million, respectively, for the first half of 2021."
Bluestein added, "With the public and private equity markets performing exceptionally well, our technology and life sciences portfolio companies are benefitting from multiple ways to raise new capital or achieve liquidity events. Our equity and warrant portfolio has continued to march in parallel with the public markets, with 26 of our portfolio companies announcing or completing exit events year-to-date, of which 10 have completed initial public offerings. This has generated record undistributed earnings spillover of over $160 million, giving us additional flexibility to continue to invest in our team and platform for the long term while also delivering strong shareholder returns."
Q2 2021 Review and Operating Results
Debt Investment Portfolio
Hercules delivered new debt and equity commitments totaling $440.8 million and fundings totaling $278.7 million.
During the second quarter, Hercules realized early loan repayments of $167.9 million, which along with normal scheduled amortization of $19.6 million, resulted in total debt repayments of $187.5 million.
The new debt investment origination and funding activities lead to a net debt investment portfolio increase of $56.8 million during the second quarter, on a cost basis.
The Company's total investment portfolio, (at cost and fair value) by category, quarter-over-quarter is highlighted below:
Total Investment Portfolio: Q2 2021 to Q1 2021
Equity & Other (in millions) Debt Investments Warrants Total Portfolio Balances at Cost at 3/31/21 $
2,182.0
$
196.5
$
25.3
$
2,403.8
New fundings(a) 268.1
10.1
0.9
279.1
Fundings assigned to External Funds (30.3
)
(1.3
)
(0.1
)
(31.7
)
Principal payments received on investments (19.6
)
—
—
(19.6
)
Early payoffs (167.9
)
—
—
(167.9
)
Net changes attributed to conversions, liquidations, and fees 6.5
(70.2
)
(1.0
)
(64.7
)
Net activity during Q2 2021 56.8
(61.4
)
(0.2
)
(4.8
)
Balances at Cost at 6/30/21 $
2,238.8
$
135.1
$
25.1
$
2,399.0
Balances at Value at 3/31/21 $
2,185.1
$
237.3
$
42.0
$
2,464.4
Net activity during Q2 2021 56.8
(61.4
)
(0.2
)
(4.8
)
Net change in unrealized appreciation (depreciation) 1.5
55.1
4.9
61.5
Total net activity during Q2 2021 58.3
(6.3
)
4.7
56.7
Balances at Value at 6/30/21 $
2,243.4
$
231.0
$
46.7
$
2,521.1
(a) New fundings amount includes $3.0 million associated with revolver loans during Q2 2021. Debt Investment Portfolio Balances by Quarter
(in millions) Q2 2021 Q1 2021 Q4 2020 Q3 2020 Q2 2020 Ending Balance at Cost $2,238.8
$2,182.0
$2,099.5
$2,283.7
$2,278.9
Weighted Average Balance $2,192.0
$2,119.0
$2,246.0
$2,217.0
$2,248.0
Debt Investment Portfolio Composition by Quarter
(% of debt investment portfolio) Q2 2021 Q1 2021 Q4 2020 Q3 2020 Q2 2020 First Lien Senior Secured 82.1%
82.7%
84.2%
85.5%
83.5%
Floating Rate w/Floors 96.8%
96.8%
96.9%
97.9%
97.9%
Effective Portfolio Yield and Core Portfolio Yield ("Core Yield")
The effective yield on Hercules' debt investment portfolio was 12.7% during Q2 2021, as compared to 13.2% for Q1 2021. The Company realized $167.9 million of early loan repayments in Q2 2021 compared to $191.5 million in Q1 2021, or a decrease of 12.3%. Effective yields generally include the effects of fees and income accelerations attributed to early loan repayments, and other one-time events. Effective yields are materially impacted by the elevated or reduced levels of early loan repayments and derived by dividing total investment income by the weighted average earning investment portfolio assets outstanding during the quarter, which excludes non-interest earning assets such as warrants and equity investments.
Core yield, a non-GAAP measure, was 11.5% during Q2 2021, within the Company's expected range of 11.0% to 12.0%, and decreased slightly compared to 11.6% in Q1 2021. Hercules defines core yield as yields that generally exclude any benefit from income related to early repayments attributed to the acceleration of unamortized income and prepayment fees and includes income from expired commitments.
Income Statement
Total investment income increased to $69.6 million for Q2 2021, compared to $68.0 million in Q2 2020. The increase is primarily attributable to an increase in total fee income between periods.
Non-interest and fee expenses were $17.1 million in Q2 2021 versus $15.6 million for Q2 2020. The increase was due to higher employee compensation and stock-based compensation expenses.
Interest expense and fees were $16.7 million in Q2 2021, compared to $16.7 million in Q2 2020.
The Company had a weighted average cost of borrowings comprised of interest and fees, of 5.4% in Q2 2021, as compared to 5.0% for Q2 2020. The increase is primarily due to the acceleration of fee recognition for the partial paydown of the SBA debentures and securitizations, due to the reinvestment period ending.
NII – Net Investment Income
NII for Q2 2021 was $37.0 million, or $0.32 per share, based on 114.7 million basic weighted average shares outstanding, compared to $35.7 million, or $0.32 per share, based on 111.6 million basic weighted average shares outstanding in Q2 2020. The increase is primarily attributable to an increase in the total fee income between periods.
Continued Credit Discipline and Strong Credit Performance
Hercules' net cumulative realized gain/(loss) position, since its first origination activities in October 2004 through June 30, 2021, (including net loan, warrant and equity activity) on investments, totaled ($86.2) million, on a GAAP basis, spanning over 16 years of investment activities.
When compared to total new debt investment commitments during the same period of over $12.0 billion, the total realized gain/(loss) since inception of ($86.2) million represents approximately 72 basis points "bps," or 0.72%, of cumulative debt commitments, or an effective annualized loss rate of 4.0 bps, or 0.04%.
Realized Gains/(Losses)
During Q2 2021, Hercules had net realized losses of ($14.3) million comprised of gross realized gains of $47.8 million due to the sale of equity and warrant investments, offset by ($62.1) million of gross realized losses primarily due to the write-off of one legacy equity investment that had a fair value of $0.
Unrealized Appreciation/(Depreciation)
During Q2 2021, Hercules recorded $60.0 million of net unrealized appreciation, primarily from net unrealized appreciation from our debt, equity and warrant investments.
Portfolio Asset Quality
As of June 30, 2021, the weighted average grade of the debt investment portfolio, at fair value, improved to 1.93, compared to 2.01 as of March 31, 2021, based on a scale of 1 to 5, with 1 being the highest quality. Hercules' policy is to generally adjust the credit grading down on its portfolio companies as they approach their expected need for additional growth equity capital to fund their respective operations for the next 9-14 months. Various companies in the Company's portfolio will require additional rounds of funding from time to time to maintain their operations.
Additionally, Hercules may selectively downgrade portfolio companies, from time to time, if they are not meeting the Company's financing criteria, or underperforming relative to their respective business plans.
As of June 30, 2021, grading of the debt investment portfolio at fair value, excluding warrants and equity investments, was as follows:
Credit Grading at Fair Value, Q2 2021 - Q2 2020 ($ in millions) Q2
2021
Q1
2021
Q4
2020
Q3
2020
Q2
2020
Grade 1 - High $
637.2
28.4
%
$
497.5
22.8
%
$
411.0
19.6
%
$
406.5
17.9
%
$
443.6
20.1
%
Grade 2 $
1,192.7
53.1
%
$
1,240.7
56.8
%
$
1,027.9
49.1
%
$
1,053.1
46.5
%
$
877.9
39.6
%
Grade 3 $
403.8
18.0
%
$
426.2
19.5
%
$
621.3
29.7
%
$
772.3
34.1
%
$
849.7
38.3
%
Grade 4 $
8.4
0.4
%
$
20.4
0.9
%
$
25.3
1.2
%
$
26.7
1.2
%
$
25.0
1.1
%
Grade 5 - Low $
1.3
0.1
%
$
0.2
0.0
%
$
8.9
0.4
%
$
5.9
0.3
%
$
20.1
0.9
%
Weighted Avg. 1.93
2.01
2.16
2.22
2.30
Non-Accruals
Non-accruals decreased slightly as a percentage of the overall investment portfolio in the second quarter of 2021. As of June 30, 2021, the Company had three (3) debt investments on non-accrual with an investment cost and fair value of approximately $23.0 million and $7.7 million, respectively, or 1.0% and 0.3% as a percentage of the Company's total investment portfolio at cost and value, respectively.
Compared to March 31, 2021, the Company had four (4) debt investments on non-accrual with an investment cost and fair value of approximately $24.1 million and $8.0 million, respectively, or 1.0% and 0.3% as a percentage of the total investment portfolio at cost and value, respectively.
Q2 2021 Q1 2021 Q4 2020 Q3 2020 Q2 2020 Total Investments at Cost $2,399.0
$2,403.8
$2,315.4
$2,505.8
$2,501.4
Loans on non-accrual as a % of Total Investments at Value 0.3%
0.3%
0.5%
0.3%
0.5%
Loans on non-accrual as a % of Total 1.0%
1.0%
1.3%
0.9%
2.4%
Investments at Cost Liquidity and Capital Resources
The Company ended Q2 2021 with $610.0 million in available liquidity, including $18.4 million in unrestricted cash and cash equivalents, and $591.6 million in available credit facilities and SBA Debentures, subject to existing terms and advance rates and regulatory and covenant requirements.
Bank Facilities
As of June 30, 2021, there were $1.7 million outstanding borrowings under the Hercules' $400.0 million committed credit facility with Union Bank as Agent and no outstanding borrowings under the Hercules' $75.0 million committed credit facility with Wells Fargo Capital Finance.
Leverage
As of June 30, 2021, Hercules' GAAP leverage ratio, including its Small Business Administration "SBA" debentures, was 87.7%. Hercules' regulatory leverage, or debt-to-equity ratio, excluding its SBA debentures, was 83.8% and net regulatory leverage, a non-GAAP measure (excluding cash of approximately $18.5 million), was 82.4%. Hercules' net leverage ratio, including its SBA debentures, was 86.4%.
Available Unfunded Commitments – Representing 12.7% of Total Assets
The Company's unfunded commitments and contingencies consist primarily of unused commitments to extend credit in the form of loans to select portfolio companies. A portion of these unfunded contractual commitments are dependent upon the portfolio company reaching certain milestones in order to gain access to additional funding. Furthermore, the Company's credit agreements contain customary lending provisions that allow us relief from funding obligations for previously made commitments. In addition, since a portion of these commitments may also expire without being drawn, unfunded contractual commitments do not necessarily represent future cash requirements.
As of June 30, 2021, the Company had $327.3 million of available unfunded commitments at the request of the portfolio company and unencumbered by any milestones, including undrawn revolving facilities, representing 12.7% of Hercules' total assets. This increased from the previous quarter of $257.9 million of available unfunded commitments or 10.0% of Hercules' total assets.
Existing Pipeline and Signed Term Sheets
After closing $440.8 million in new debt and equity commitments in Q2 2021, Hercules has pending commitments of $402.5 million in signed non-binding term sheets outstanding as of July 26, 2021. Since the close of Q2 2021 and as of July 26, 2021, Hercules has closed new debt and equity commitments of $27.0 million and funded $23.4 million.
Signed non-binding term sheets are subject to satisfactory completion of Hercules' due diligence and final investment committee approval process as well as negotiations of definitive documentation with the prospective portfolio companies. These non-binding term sheets generally convert to contractual commitments in approximately 90 days from signing and some portion may be assigned or allocated to private funds managed by Hercules Adviser prior to or after closing. It is important to note that not all signed non-binding term sheets are expected to close and do not necessarily represent future cash requirements or investments.
Net Asset Value
As of June 30, 2021, the Company's net assets were $1.36 billion, compared to $1.32 billion at the end of Q1 2021. NAV per share increased 3.1% to $11.71 on 115.9 million outstanding shares of common stock as of June 30, 2021, compared to $11.36 on 115.8 million outstanding shares of common stock as of March 31, 2021. The increase in NAV per share was primarily attributed to the net change in unrealized appreciation and a decrease in liabilities between periods.
Interest Rate Sensitivity
Hercules has an asset sensitive debt investment portfolio with 96.8% of its debt investment portfolio being priced at floating interest rates as of June 30, 2021, with a Prime or LIBOR-based interest rate floor, combined with 99.9% of its outstanding debt borrowings bearing fixed interest rates, leading to higher net investment income sensitivity.
Based on Hercules' Consolidated Statement of Assets and Liabilities as of June 30, 2021, the following table shows the approximate annualized increase/(decrease) in components of net income resulting from operations of hypothetical base rate changes in interest rates, such as Prime Rate, assuming no changes in Hercules' debt investments and borrowings. These estimates are subject to change due to the impact from active participation in the Company's equity ATM program and any future equity offerings.
(in thousands) Interest Interest Net EPS(2) Basis Point Change Income(1) Expense Income (75)
$
(3)
$
(21)
$
18
$
-
(50)
$
(3)
$
(14)
$
11
$
-
(25)
$
(3)
$
(7)
$
4
$
-
25
$
3,425
$
7
$
3,418
$
0.03
50
$
6,893
$
14
$
6,879
$
0.06
75
$
10,339
$
21
$
10,318
$
0.09
100
$
13,862
$
28
$
13,834
$
0.12
200
$
29,236
$
56
$
29,180
$
0.25
(1) Source: Hercules Capital Form 10-Q for Q2 2021 (2) EPS calculated on basic weighted shares outstanding of 114,654. Estimates are subject to change due to impact from active participation in the Company's equity ATM program and any future equity offerings. Existing Equity and Warrant Portfolio
Equity Portfolio
Hercules held equity positions in 67 portfolio companies with a fair value of $229.9 million and a cost basis of $133.8 million as of June 30, 2021. On a fair value basis, 62.6% or $143.9 million is related to existing public equity positions.
Warrant Portfolio
Hercules held warrant positions in 93 portfolio companies with a fair value of $46.7 million and a cost basis of $25.1 million as of June 30, 2021. On a fair value basis, 31.4% or $14.7 million is related to existing public warrant positions.
Portfolio Company IPO and M&A Activity in Q2 2021 and YTD Q3 2021
IPO Activity
As of July 26, 2021, Hercules held debt, warrant or equity positions in 10 portfolio companies that have completed their IPOs and eight (8) companies that have registered for their IPOs or have entered into definitive agreements to go public via a merger or special purpose acquisition company "SPAC," including:
Completed:
- In July 2021, Hercules' portfolio company Couchbase, Inc. (NASDAQ:BASE), a provider of a leading modern database for enterprise applications, completed its initial public offering of 8.3 million shares of common stock at an initial offering price of $24.00 per share on the Nasdaq Global Select Market. Hercules initially committed $70.0 million in venture debt financing beginning in August 2018 and currently holds warrants for 105,530 shares of common stock as of June 30, 2021.
- In July 2021, Hercules' portfolio company Wheels Up Partners LLC (NYSE:UP), a provider of subscription club memberships for private-jet flyers, completed its reverse merger initial public offering with Aspirational Consumer Lifestyle Corp. (NYSE:ASPL), a special purpose acquisition company. Hercules initially committed $23.0 million in venture debt financing beginning in December 2017.
- In July 2021, former Hercules' portfolio company Rapid Micro Biosystems (NASDAQ:RPID), a provider of an automated microbial quality control device and platform, completed its initial public offering of 7.9 million shares of common stock at an initial offering price of $20.00 per share on the Nasdaq Global Select Market. Hercules initially committed $18.0 million in venture debt financing beginning in March 2018.
- In June 2021, Hercules' portfolio company Century Therapeutics, Inc. (NASDAQ:IPSC), a preclinical biotech developing allogeneic stem cell treatments for multiple cancers, completed its initial public offering of 10.6 million shares of common stock at an initial offering price of $20.00 per share on the Nasdaq Global Select Market. Hercules initially committed $20.0 million in venture debt financing beginning in September 2020 and currently holds warrants for 16,112 shares of common stock as of June 30, 2021.
- In June 2021, Hercules' portfolio company Sprinklr, Inc. (NYSE:CXM), a developer of a social media management platform designed to provide digital transformation for enterprise businesses, completed its initial public offering of 16.6 million shares of common stock at an initial offering price of $16.00 per share on the New York Stock Exchange. Hercules currently holds 700,000 shares of common stock as of June 30, 2021.
- In June 2021, Hercules' portfolio company Zeta Global Holdings (NYSE:ZETA), a provider of a SaaS-based customer relationship management (CRM) platform and professional marketing services, completed its initial public offering of 14.8 million shares of common stock at an initial offering price of $10.00 per share on the New York Stock Exchange. Hercules initially committed $15.0 million in venture debt financing beginning in November 2007 and currently holds 295,861 shares of common stock as of June 30, 2021.
- In June 2021, Hercules' portfolio company Xometry (NASDAQ:XMTR), a leading AI-enabled marketplace for on-demand manufacturing, completed its initial public offering of 6.9 million shares of common stock at an initial offering price of $44.00 per share on the Nasdaq Global Select Market. Hercules initially committed $15.0 million in venture debt financing beginning in May 2018 and currently holds warrants for 87,784 shares of Preferred Series B stock as of June 30, 2021.
- In June 2021, Hercules' portfolio company Proterra Inc. (NASDAQ:PTRA), a leading commercial electric vehicle technology and manufacturing company, completed its reverse merger initial public offering with ArcLight Clean Transition Corp. (NASDAQ:ACTC), a special purpose acquisition company. Hercules initially committed $30.0 million in venture debt financing beginning in May 2015 and currently holds 455,890 shares of common stock as of June 30, 2021.
- In June 2021, Hercules' portfolio company 23andMe Inc. (NASDAQ:ME), a provider of consumer DNA-testing products, completed its reverse merger initial public offering with VG Acquisition Corp. (NYSE:VGAC), a special purpose acquisition company. Hercules currently holds 828,360 shares of common stock as of June 30, 2021.
- In April 2021, Hercules' portfolio company Privia Health Group, Inc. (NASDAQ:PRVA), a technology-driven, national physician enablement company that collaborates with medical groups, health plans and health systems, completed its initial public offering of 19.5 million shares of common stock at an initial offering price of $23.00 per share on the Nasdaq Global Select Market. Hercules initially committed $35.0 million in venture debt financing beginning in August 2016.
In Registration or SPAC:
- In July 2021, Hercules' portfolio company Gelesis Inc., a biotherapeutics company advancing superabsorbent hydrogels to treat excess weight and metabolic disorders, announced it has entered into a definitive agreement for a reverse merger initial public offering with Capstar Special Purpose Acquisition Corp. (NYSE:CPSR), a special purpose acquisition company. Upon completion of the merger, the combined company will be listed on the New York Stock Exchange under the ticker symbol "GLS." Hercules initially committed $3.0 million in venture debt financing in August 2008 and currently holds 227,013 shares of common stock, 243,432 shares of Preferred Series A-1 stock and 191,626 shares of Preferred Series A-2 stock as of June 30, 2021.
- In July 2021, Hercules' portfolio company Nextdoor, a provider of a social network that connects neighbors, announced it has entered into a definitive agreement for a reverse merger initial public offering with Khosla Ventures Acquisition Co. II (NASDAQ:KVSB), a special purpose acquisition company. Upon completion of the merger, the combined company will be listed on the Nasdaq Global Select Market under the ticker symbol "KIND." Hercules currently holds 328,190 shares of common stock as of June 30, 2021.
- In July 2021, Hercules' portfolio company Planet Labs, an earth data and analytics company, announced it has entered into a definitive agreement for a reverse merger initial public offering with dMY Technology Group IV Inc. (NYSE:DMYQ), a special purpose acquisition company. Upon completion of the merger, the combined company will be listed on the New York Stock Exchange under the ticker symbol "PL." Hercules initially committed $25.0 million in venture debt financing beginning in June 2019 and currently holds warrants for 357,752 shares of common stock as of June 30, 2021.
- In May 2021, Hercules' portfolio company Valo Health LLC, a technology company using human-centric data and artificial intelligence powered computation to transform the drug discovery and development process, announced it has entered into a definitive agreement for a reverse merger initial public offering with Khosla Ventures Acquisition Co. (NASDAQ:KVAC), a special purpose acquisition company. Upon completion of the merger, the combined company will be listed on the Nasdaq Global Select Market under the ticker symbol "VH." Hercules initially committed $20.0 million in venture debt financing beginning in June 2020 and currently holds 510,308 shares of Preferred Series B stock and warrants for 102,216 shares of common stock as of June 30, 2021.
- In March 2021, Hercules' portfolio company Rocket Lab, a developer of launch and space systems, announced it has entered into a definitive agreement for a reverse merger initial public offering with Vector Acquisition Corp. (NASDAQ:VACQ), a special purpose acquisition company. Upon completion of the merger, Rocket Lab will be listed on the Nasdaq Global Select Market under the ticker symbol "RKLB." Hercules initially committed $100.0 million in venture debt financing beginning in June 2021.
- In March 2021, Hercules' portfolio company VELO3D, a developer of metal laser sintering printing machines intended to offer 3D printing, announced it has entered into a definitive agreement for a reverse merger initial public offering with Jaws Spitfire Acquisition Corp. (NYSE:SPFR), a special purpose acquisition company. Upon completion of the merger, VELO3D will be listed on the New York Stock Exchange under the ticker symbol "VLD." Hercules initially committed $12.5 million in venture debt financing beginning in May 2021.
- In March 2021, Hercules' portfolio company Pineapple Energy, LLC, a U.S. operator and consolidator of residential solar, battery storage and grid services solutions, announced that it entered into a definitive merger agreement with Communications Systems, Inc. (NASDAQ:JCS), and IoT intelligent edge products and services company. Upon closing, CSI will commence doing business as Pineapple Energy, and expects shares of the combined company to continue to trade on the Nasdaq Global Select Market under the new ticker symbol "PEGY." Hercules initially committed $12.3 million in venture debt financing beginning in December 2010 and currently holds 17,647 shares of Class A Units as of June 30, 2021.
- In February 2021, Nerdy, the parent company of Hercules' portfolio company Varsity Tutors, a technology developer of an online tutoring platform, announced it has entered into a definitive agreement for a reverse merger initial public offering with TPG Pace Tech Opportunities (NYSE:PACE), a special purpose acquisition company. Upon completion of the merger, Nerdy will be listed on the New York Stock Exchange under the ticker symbol "NRDY." Hercules initially committed $50.0 million in venture debt financing beginning in August 2019.
There can be no assurances that companies that have yet to complete their IPOs will do so.
M&A Activity
- In June 2021, Hercules' portfolio company ExtraHop Networks Inc., a cloud-native network detection and response provider, announced that they entered into an agreement to be acquired by private equity firms Bain Capital and Crosspoint Capital for $900.0 million. The acquisition was completed in July. Hercules initially committed $15.0 million in venture debt financing beginning in September 2020 and currently holds warrants for 154,784 shares of common stock as of June 30, 2021.
- In May 2021, Hercules' portfolio company Greenphire, a leader in global clinical trial financial process automation, announced that they have reached an agreement to be acquired by Thoma Bravo, a leading private equity investment firm focused on the software and technology-enabled services sector. Terms of the acquisition were not disclosed. Hercules initially committed $6.0 million in venture debt (via Ares Capital venture portfolio acquisition) financing beginning in November 2017.
- In May 2021, Hercules' portfolio company Vela Trading Systems LLC, an independent provider of trading and market access technology for global multi-asset electronic trading, announced that they have merged with Exegy Inc., a provider of low-latency global market data solutions, predictive trading signals and hardware training platforms for the financial services industry. Terms of the acquisition were not disclosed. The merger was backed by Marlin Equity Partners, a global investment firm with over $7.5 billion of capital commitments under management. Hercules initially committed $20.0 million in venture debt financing beginning in June 2017.
- In April 2021, Hercules' portfolio company Message Systems (a.k.a. SparkPost), a worldwide provider of message management solutions and services for email service providers, social networks and large enterprises, announced that they have reached an agreement to be acquired by MessageBird BV, a provider of cloud-based communications services, for approximately $600.0 million. Hercules initially committed $25.0 million in venture debt financing beginning in January 2015.
Subsequent Events
1. As of July 26, 2021, Hercules has:
- Funded $23.4 million to new and existing commitments since the close of the second quarter 2021.
- Pending commitments (signed non-binding term sheets) of $402.5 million.
The table below summarizes the Company's year-to-date closed and pending commitments as follows:
Closed Commitments and Pending Commitments (in millions)
January 1 – June 30, 2021 Closed Commitments(a)
$971.7
Q3 2021 Closed Commitments (as of July 26, 2021)(b)
$27.0
Year-to-Date Closed Commitments
$998.7
Q3 2021 Pending Commitments (as of July 26, 2021)(b)
$402.5
Year-to-Date 2021 Closed and Pending Commitments
$1,401.2
Notes:
- Closed Commitments may include renewals of existing credit facilities and equity commitments. Not all Closed Commitments result in future cash requirements. Commitments generally fund over the two succeeding quarters from close.
- Not all pending commitments (signed non-binding term sheets) are expected to close and do not necessarily represent any future cash requirements.
2. On July 1, 2021, the Company fully redeemed the aggregate outstanding $75.0 million of principal and $0.6 million of accrued interest pursuant to the redemption terms of the April 2025 Notes Indenture. The Company accelerated $1.5 million of debt issuance costs associated with the extinguishment of the debt.
Conference Call
Hercules has scheduled its second quarter 2021 financial results conference call for July 29, 2021 at 2:00 p.m. PT (5:00 p.m. ET). To listen to the call, please dial (877) 304-8957 (or (408) 427-3709 internationally) and reference Conference ID: 1598912 if asked, approximately 10 minutes prior to the start of the call. A taped replay will be made available approximately three hours after the conclusion of the call and will remain available for seven days. To access the replay, please dial (855) 859-2056 or (404) 537-3406 and enter the passcode 1598912.
About Hercules Capital, Inc.
Hercules Capital, Inc. (NYSE:HTGC) is the leading and largest specialty finance company focused on providing senior secured venture growth loans to high-growth, innovative venture capital-backed companies in a broad variety of technology, life sciences and sustainable and renewable technology industries. Since inception (December 2003), Hercules has committed more than $12.0 billion to over 530 companies and is the lender of choice for entrepreneurs and venture capital firms seeking growth capital financing. Companies interested in learning more about financing opportunities should contact info@htgc.com, or call 650.289.3060.
Hercules' common stock trades on the New York Stock Exchange (NYSE) under the ticker symbol "HTGC." In addition, Hercules has one retail bond issuance of 6.25% Notes due 2033 (NYSE:HCXY).
Category: Earnings
Forward-Looking Statements
This press release may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. You should understand that under Section 27A(b)(2)(B) of the Securities Act of 1933, as amended, and Section 21E(b)(2)(B) of the Securities Exchange Act of 1934, as amended, or the Exchange Act, the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 do not apply to forward-looking statements made in periodic reports we file under the Exchange Act.
The information disclosed in this press release is made as of the date hereof and reflects Hercules' most current assessment of its historical financial performance. Actual financial results filed with the SEC may differ from those contained herein due to timing delays between the date of this release and confirmation of final audit results. These forward-looking statements are not guarantees of future performance and are subject to uncertainties and other factors that could cause actual results to differ materially from those expressed in the forward-looking statements including, without limitation, the risks, uncertainties, including the uncertainties surrounding the current market volatility, and other factors the Company identifies from time to time in its filings with the SEC. Although Hercules believes that the assumptions on which these forward-looking statements are based are reasonable, any of those assumptions could prove to be inaccurate and, as a result, the forward-looking statements based on those assumptions also could be incorrect. You should not place undue reliance on these forward-looking statements. The forward-looking statements contained in this release are made as of the date hereof, and Hercules assumes no obligation to update the forward-looking statements for subsequent events.
HERCULES CAPITAL, INC. CONSOLIDATED STATEMENTS OF ASSETS AND LIABILITIES (dollars in thousands, except per share data) June 30, 2021 December 31, 2020 Assets Investments: Non-control/Non-affiliate investments (cost of $2,307,766 and $2,175,651, respectively) $ 2,444,849
$ 2,288,338
Control investments (cost of $77,901 and $65,257, respectively) 66,491
57,400
Affiliate investments (cost of $13,307 and $74,450, respectively) 9,750
8,340
Total investments in securities, at value (cost of $2,398,974 and $2,315,358, respectively) 2,521,090
2,354,078
Cash and cash equivalents 18,447
198,282
Restricted cash 5,766
39,340
Interest receivable 19,063
19,077
Right of use asset 8,039
9,278
Other assets 6,167
3,942
Total assets $ 2,578,572
$ 2,632,997
Liabilities Debt (net of debt issuance costs)(1) $ 1,177,515
$ 1,286,638
Accounts payable and accrued liabilities 36,886
36,343
Operating lease liability 7,813
9,312
Total liabilities $ 1,222,214
$ 1,332,293
Net assets consist of: Common stock, par value 116
115
Capital in excess of par value 1,163,910
1,158,198
Total distributable earnings 192,332
133,391
Total net assets $ 1,356,358
$ 1,291,704
Total liabilities and net assets $ 2,578,572
$ 2,623,997
Shares of common stock outstanding ($0.001 par value, 200,000,000 authorized) 115,867
114,726
Net asset value per share $ 11.71
$ 11.26
(1) The Company's SBA Debentures, February 2025 Notes, June 2025 Notes, 2033 Notes, April 2025 Notes, 2022 Notes, 2027 Asset-Backed Notes, 2028 Asset-Backed Notes, 2022 Convertible Notes, July 2024 Notes, and March 2026 A and B Notes, as each term is defined herein, are presented net of the associated debt issuance costs for each instrument. HERCULES CAPITAL, INC. CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands, except per share data) Three Months Ended June 30, Six Months Ended June 30, 2021
2020
2021
2020
Investment income: Interest and dividend income Non-control/Non-affiliate investments $ 60,276
$ 62,667
$ 123,258
$ 128,005
Control investments 1,029
731
1,828
1,377
Affiliate investments 1
157
2
377
Total interest income 61,306
63,555
125,088
129,759
Fee income Commitment, facility and loan fee income Non-control/Non-affiliate investments 5,263
3,511
8,666
7,707
Control investments 15
5
23
10
Total commitment, facility and loan fee income 5,278
3,516
8,689
7,717
One-time fee income Non-control/Non-affiliate investments 2,975
897
4,541
4,111
Total one-time fee income 2,975
897
4,541
4,111
Total fee income 8,253
4,413
13,230
11,828
Total investment income 69,559
67,968
138,318
141,587
Operating expenses: Interest 14,490
15,076
29,240
29,608
Loan fees 2,220
1,650
5,020
3,444
General and administrative Legal expenses 526
991
954
1,890
Tax expenses 1,746
899
3,184
2,034
Other expenses 3,542
3,973
6,710
7,998
Total general and administrative 5,814
5,863
10,848
11,922
Employee compensation Compensation and benefits 8,349
7,180
18,153
15,394
Stock-based compensation 2,926
2,515
5,670
4,955
Total employee compensation 11,275
9,695
23,823
20,349
Total gross operating expenses 33,799
32,284
68,931
65,323
Expenses allocated to the Adviser Subsidiary (1,204)
—
(2,137)
—
Total net operating expenses 32,595
32,284
66,794
65,323
Net investment income 36,964
35,684
71,524
76,264
Net realized and change in unrealized appreciation (depreciation) on investments: Net realized gain (loss) on investments Non-control/Non-affiliate investments 47,861
141
55,631
7,108
Affiliate investments (62,143)
—
(62,143)
—
Total net realized gain (loss) on investments (14,282)
141
(6,512)
7,108
Net change in unrealized appreciation (depreciation) on investments Non-control/Non-affiliate investments 3,075
23,613
21,097
(34,816)
Control investments (5,255)
2,642
(3,553)
(5,209)
Affiliate investments 62,229
(315)
64,338
(10,305)
Total net change in unrealized appreciation (depreciation) on investments 60,049
25,940
81,882
(50,330)
Total net realized and change in unrealized appreciation (depreciation) on investments: 45,767
26,081
75,370
(43,222)
Net increase (decrease) in net assets resulting from operations $ 82,731
$ 61,765
$ 146,894
$ 33,042
Net investment income before investment gains and losses per common share: Basic $ 0.32
$ 0.32
$ 0.62
$ 0.69
Change in net assets resulting from operations per common share: Basic $ 0.71
$ 0.55
$ 1.27
$ 0.29
Diluted $ 0.65
$ 0.55
$ 1.21
$ 0.29
Weighted average shares outstanding: Basic 114,654
111,558
114,480
110,256
Diluted 129,572
111,729
122,188
110,504
Distributions paid per common share: Basic $ 0.39
$ 0.32
$ 0.76
$ 0.72
View source version on businesswire.com: https://www.businesswire.com/news/home/20210729005948/en/
-
View Full Article Hide Full Article
PHILADELPHIA, June 22, 2021 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ:IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced the closing of its initial public offering of 12,132,500 shares of its common stock at a public offering price of $20.00 per share, which includes the full exercise by the underwriters of their option to purchase 1,582,500 additional shares of common stock. The aggregate gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Century, were approximately $242.7 million. All the shares of common stock were offered by Century.
J.P. Morgan, BofA Securities, SVB Leerink and Piper Sandler acted as joint book-running managers for the offering.
A registration statement relating to the shares being sold in this offering was filed with the Securities and Exchange Commission and became effective on June 17, 2021. The offering was made only by means of a prospectus. Copies of the final prospectus may be obtained from: J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by email at prospectus-eq_fi@jpmorgan.com, or by telephone at (866) 803-9204; BofA Securities, NC1-004-03-43, 200 North College Street, 3rd Floor, Charlotte, NC 28255-0001, Attention: Prospectus Department, or by email at dg.prospectus_requests@bofa.com, 1-800-294-1322; SVB Leerink LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, by telephone at 1-800-808-7525 ex. 6105 or by email at syndicate@svbleerink.com; and Piper Sandler & Co., Attn: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, Minnesota 55402, by telephone at (800) 747-3924 or by email at prospectus@psc.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
About Century Therapeutics
Century Therapeutics (NASDAQ:IPSC) is harnessing the power of adult stem cells to develop curative cell therapy products for cancer that we believe will allow us to overcome the limitations of first-generation cell therapies. Our genetically engineered, iPSC-derived iNK and iT cell products are designed to specifically target hematologic and solid tumor cancers. We believe our commitment to developing off-the-shelf cell therapies will expand patient access and provides an unparalleled opportunity to advance the course of cancer care.
Forward-Looking Statements
This press release contains forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements. Each forward-looking statement is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statement. Applicable risks and uncertainties include those identified under the heading "Risk Factors" in Century's registration statement on Form S-1. These forward-looking statements speak only as of the date of this press release. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by applicable law.
Investor Contact:
investor.relations@centurytx.com
267.857.1080Media Contact:
media@centurytx.com